Latest Launch in Cellectis bioresearch’s cGPS® Product Family Enables Screening Against Difficult-to-Express Drug Targets

CBR_PR_Kit_Double_30102009.pdf

Romainville, October 5th, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today launched cGPS^® CHO-K1 duo – its third research kit now available. cGPS^® CHO-K1 duo enables the targeted integration of several genes or regulatory elements at two independent genomic sites in the CHO-K1 cell line.

"The cGPS^® CHO-K1 duo kit enables industrial high-throughput screening platforms to screen drug candidates against difficult-to-express targets", commented Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "This new product fits perfectly into our cGPS^® line, which brings speed, ease-of-use and robust performances to processes that were previously lengthy, burdensome and erratic".

The discovery of a new drug usually involves screening hundreds of thousands of compounds against cells expressing the target of interest. Many targets (such as membrane receptors) cannot be adequately over-expressed, due to their excessive toxicity or a requirement for the assembly of several subunits. The cGPS^® CHO-K1 duo kit developed by Cellectis bioresearch enables stable and regulated expression of several protein subunits in the CHO-K1 cell line, the most frequently used for screening. It also enables the integration of an inducible expression system, which can attenuate the toxic effects of certain drug targets.

The targeted integration kit ranges - cGPS^® (cellular Genome Positioning System) and cGPS^® Custom - are available for purchase at www.cellectis-bioresearch.com